Cantor Fitzgerald Forecasts PVLA FY2025 Earnings

Palvella Therapeutics (NASDAQ:PVLA - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Palvella Therapeutics in a report issued on Monday, May 19th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($2.60) per share for the year. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($3.69) per share.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.40) by $2.66.

Other research analysts have also issued research reports about the company. Canaccord Genuity Group cut their price target on Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Stifel Nicolaus began coverage on Palvella Therapeutics in a report on Wednesday, March 26th. They issued a "buy" rating and a $45.00 target price on the stock. Chardan Capital assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, April 9th. They set a "buy" rating and a $50.00 price target for the company. TD Cowen started coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a "buy" rating and a $44.00 price objective on the stock. Finally, Jones Trading assumed coverage on shares of Palvella Therapeutics in a report on Tuesday, March 25th. They set a "buy" rating and a $45.00 price objective for the company. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Palvella Therapeutics currently has a consensus rating of "Buy" and an average price target of $46.29.

Palvella Therapeutics Trading Up 7.3%

Shares of NASDAQ:PVLA traded up $1.61 during trading on Wednesday, reaching $23.72. The stock had a trading volume of 138,230 shares, compared to its average volume of 68,642. The business's fifty day moving average is $24.12. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $29.27. The stock has a market capitalization of $262.25 million, a PE ratio of -1.96 and a beta of 0.10.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new stake in shares of Palvella Therapeutics in the fourth quarter worth $256,000. BML Capital Management LLC bought a new stake in shares of Palvella Therapeutics during the 4th quarter worth $506,000. Geode Capital Management LLC bought a new stake in shares of Palvella Therapeutics during the 4th quarter worth $171,000. Nantahala Capital Management LLC purchased a new position in Palvella Therapeutics in the fourth quarter worth $3,001,000. Finally, Adams Street Partners LLC bought a new position in Palvella Therapeutics in the fourth quarter valued at $4,916,000. 40.11% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins purchased 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average cost of $20.13 per share, with a total value of $50,325.00. Following the completion of the transaction, the director now owns 183,171 shares of the company's stock, valued at $3,687,232.23. The trade was a 1.38% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 20.50% of the company's stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.